Geleneksel Çin Tıbbı

Kaptchuk TJ. The web that has no weaver. New York: Congdon and Weed,1983
Patridge E., Gareiss P., Kinch MS, Hoyer D. (2016). An analysis of FDA-approved drugs: natural products and their derivatives. Drug discovery today, 21(2), 204-207.
Kuo YT, Chang TT, Muo CHet al., “Use of complementary traditional Chinese medicines by adult cancer patients in taiwan: a nationwide population-based study,” Integrative Cancer Therapies, vol. 17, no. 2, pp. 531–541, 2018
Zhang SY, Gu CH and Gao XD: A randomly double-blinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. J Diffic Compl Case. 8:461–464. 2009
Konkimalla VB and Efferth T: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol. 116:207–210. 2008
Wang GS: Medical uses of Mylabris in ancient China and recent studies. J Ethnopharmacol. 26:147–162. 1989
Lu CX, Nan KJ and Lei Y: Agents from amphibians with anticancer properties. Anticancer Drugs. 19:931–939. 2008.
Yoshida Y, Wang MQ, Liu JN et al: Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol. 19:359–370. 1997
Liu D and Chen Z: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem. 9:392–396. 2009
Liu J, Shi Z, Xu Z, et al: Clinical observation on treatment of non-parvicellular carcinoma of the lung with jin fu kang oral liquid. J Tradit Chin Med. 20:96–100. 2000
Hu SY. A contribution to our knowledge of ginseng. Am J Chin Med. 1977;5:1-23
Yun TK and Choi SY: Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 4:401–408. 1995
Hofseth LJ and Wargovich MJ: Inflammation, cancer, and targets of ginseng. J Nutr. 137 (Suppl 1):183S–185S. 2007
Lee TK, Johnke RM, Allison RR, et al. Radioprotective potential of ginseng. Mutagenesis. 20:237–243. 2005
Liu D and Chen Z: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem. 9:392–396. 2009
Q. Meng LF, Yau JG, Lu et al. Chemical profiling and cytotoxicity assay of bufadienolides in toad venom and toad skin. J. Ethnopharmacol., 187 (2016), pp. 74-82
Deng LJ, Hu LP, Peng QL, et al. Hellebrigenin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells through inhibition of Akt. Chemico-Biological Interactions, 219, 184-194
Meng Z, Yang P, Shen Y, et al: Pilot study of Huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009
Pan L: Practical road of "the numeral turn Chinese herbal medicine" for Shenqi fuzheng injection. Journal of China Prescription Drug. 2009, 1 (82): 37-39
Zhong ZH: Dictate history: A national new medicine that come from experiential prescription. Journal of China Prescription Drug. 2009, 1 (82): 33-36
Dong J, Su SY, Wang MY et al: Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res. 29:1372010
Dai Z, Wan X, Kang H, et al: Clinical effects of shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J Tradit Chin Med. 28:34–38. 2008
Ye L Ji K, Frewer N, et al. Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res. 32:2537–2543. 2012
Xue K, Shan F and Ji J: Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chin J Clin Oncol. 40:1318–1323. 2013
Li T, Tamada K, Abe K, et al: The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki. Immunopharmacology. 43:11–21. 19